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Abstract
Background: Biofilm formation is important in Candida albicans pathogenesis and constitutes a mechanism of
antifungal resistance. Thus, we evaluated the effect of proanthocyanidins polymer-rich fractions from Stryphnodendron
adstringens (fraction F2 and subfraction F2.4) against C. albicans biofilms.
Methods: Firstly, the antifungal activity of F2 and F2.4 against planktonic cells of Candida albicans (ATCC 10231) was
determined using broth microdilution method. Anti-biofilm effect of F2 and F2.4 was evaluated during biofilm
formation or on mature biofilm of C. albicans and compared with standard antifungals amphotericin B and
fluconazole. Metabolic activity of sessile and dispersion cells from biofilms after antifungal treatments were
measured using a tetrazolium reduction assay and the biofilm total biomass was quantified by crystal violet-based
assay. Morphological alterations after treatments were observed using scanning electron microscopy.
Results: The anti-biofilm effect of F2 and F2.4 were comparable to standard antifungals (amphotericin B and
fluconazole). F2 and F2.4 treatments reduced biofilm metabolic activity (in sessile and in dispersion cells) during
biofilm formation, and in mature biofilms, unlike fluconazole, which only prevents the biofilm formation. Treatments
with F2, F2.4 or fluconazole reduced biofilm biomass during biofilm formation, but not in mature biofilm. Amphotericin
B presented higher inhibitory effect on biofilm formation and on mature biofilm of C. albicans. F2 and F2.4 treatments
led to the appearance of dumbbell-shaped blastoconidia and of blastoconidia clusters in biofilms.
Conclusion: Proanthocyanidins polymer-rich fractions from S. adstringens successfully inhibited C. albicans planktonic
growth and biofilm development, and they represent a potential new agent for the treatment of biofilm-associated
candidiasis.
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Background
Candida spp. are commensal yeasts that, in healthy indi-
viduals, colonize mainly mucosal surfaces of the oral
cavity, and the gastrointestinal and urogenital tracts, with-
out causing disease symptoms. However, these fungi may
cause opportunistic infections in humans with certain
physiological disorders, or in patients who have become
immunocompromised or are undergoing therapy with
broad-spectrum antibiotics. About 96% of all opportun-
istic mycoses are caused by Candida sp. [1], and C. albi-
cans is still the major pathogenic species worldwide,
causing 90% of vulvovaginal candidiasis [2] and 50 –
70% of invasive candidiasis cases [3], with a mortality
rate of 30–40% [3].
In Brazil, Stryphnodendron adstringens (Mart.) Coville
(Leguminosae) is one of the most frequently used medi-
cinal plants in the treatment of vaginal infections and
wounds, and it is also used as astringent, anti-diarrhoeal,
antimicrobial or hypoglycaemic agent [4]. The stem bark
of S. adstringens is rich in tannins (10-37%) [4], repre-
senting mainly flavan-3-ols and proanthocyanidins, such
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as prodelphinidins and prorobinetinidins [5-7]. Previous
pharmacological studies have demonstrated that tannins
extracted from S. adstringens stem bark have healing
properties [8], analgesic and anti-inflammatory activity
[9] and gastric anti-ulcerogenic effects [10]. Several stud-
ies have also demonstrated that tannins from S. adstrin-
gens have inhibitory activity against parasitic protists
[11-13], viruses [14] and bacteria [9,15].
Previous reports from our group have demonstrated
the antifungal activity of fractions derived from S.
adstringens stem bark (fraction F2 and subfraction F2.4)
against planktonic cells (in suspension) from vaginal
isolates of Candida spp. [7], and against Cryptococcus
neoformans [16]. Treatment with the proanthocyanidin
polymeric tannins present in subfraction F2.4 (hexame-
ric polymer with monomeric units of prodelphinidins,
prorobinetinidins and gallic acid residues with molecu-
lar weight 2,114 Da.) also altered some virulence factors
of C. albicans as well as led to alterations in budding
and on cell wall morphology [7]. In addition, toxico-
logical studies using rodents have also reported low side
effects after treatment with proantocyanidin polymer-
rich fraction (F2) [17,18].
Biofilms are defined as heterogeneous microbial com-
munities of cells adhering to an abiotic or biotic surface,
while embedded in a polymeric extracellular matrix (pro-
duced by biofilm cells). In biofilms, microbial cells display
altered phenotypes in comparison to those observed in
planktonic cells of the same species and strain, mainly in
their increased resistance to antifungal treatments [19,20].
C. albicans biofilms are resistant to a variety of clinical an-
tifungal agents, including amphotericin B and fluconazole
[19,20], the major antifungal agents used for the treatment
of both superficial and invasive candidiasis [21].
The development of new molecules with activity
against C. albicans biofilms is paramount to add to the
limited therapeutic options currently available for the
effective treatment of Candida infections involving bio-
film formation. Previously, we showed that S. adstrin-
gens fraction F2 and subfraction F2.4 are active against
Candida albicans planktonic cells [7]. In this work, we
extend these findings by demonstrating that fraction F2
and subfraction F2.4 from S. adstringens are also effect-
ive against C. albicans biofilms, and against dispersion
biofilm cells, which are important for disease dissemin-
ation inside the host.
Methods
Microorganism
Antifungal effects were tested against Candida albicans
ATCC 10231. This strain was maintained in Sabouraud
dextrose agar (Becton, Dickinson and Company, Sparks,
USA) at 4°C and subcultured twice in the same medium
at 35°C, for 24 h before each assay.
Extraction
Stryphnodendron adstringens stem bark was collected in
São Jerônimo da Serra, Paraná, Brazil, in March 2010. A
voucher specimen was deposited at the Herbarium of
the Universidade Estadual de Maringá (HUEM #14321),
and it was identified by Prof. Dr. Cássia Mônica Sakuragui
(Federal University of Rio de Janeiro). The stem bark was
dried at room temperature and pulverized. Fraction F2
and subfraction F2.4 were prepared as described by
Ishida and co-workers [7], and kept as lyophilized ex-
tracts at -20°C in small aliquots. As previously reported,
subfraction F2.4 consists of a hexameric tannin composed
of monomeric units of prodelphinidins and prorobinetini-
dins, and gallic acid residues (molecular weight, 2,114 Da)
[7]. The method of fractions preparation was validated
by Costa et al. [22], and the subfraction 2.4 was identi-
fied by solid-state nuclear magnetic resonance (NMR)
spectrometry using a Varian spectrometer (Mercury
Plus 300 [7.02T]) operating at 75 MHz for 13C and 300
MHz for 1H. The identities of the polymeric tannin in
subfraction F2.4 were confirmed using 13C NMR, by
comparison of the spectrum obtained here with results
reported by Ishida et al. [7].
Antifungal agents
Two antifungal were used as references: fluconazole (FLC;
Pfizer, São Paulo, Brazil), diluted in water (2,000 μg/mL)
and amphotericin B (AMB; Sigma Chemical Co., USA), di-
luted in DMSO (1,600 μg/mL) and stored at -20°C.
Antifungal susceptibility tests on planktonic cells
The antifungal susceptibility of C. albicans ATCC 10231
planktonic cells was assessed by broth microdilution
assay as described in Document M27-A3 [23]. The con-
centrations tested were: 0.48 - 250 μg/mL, for fraction
F2 or subfraction F2.4; 0.03 - 16 μg/mL AMB; and 0.125 -
64 μg/mL FLC. The minimum inhibitory concentration
(MIC) value is defined as the lowest concentration that
inhibit 50% of fungal growth (IC50, for azoles) or 90% of
fungal growth (IC90, for polyenes) determined by visual in-
spection or spectrophotometric reading at 492 nm in a
microtitre plate reader (SpectraMAX 340 Tunable Micro-
plate Reader, Molecular Devices Ltd, USA) [23]. Here, we
also considered the IC50 value to be the MIC for the frac-
tion F2 and subfraction F2.4 from S. adstringens.
The MFC is defined as the lowest concentration of a
given compound that fails to produce fungal growth,
and was determined by transferring an aliquot of fungal
samples treated with concentrations higher than the MIC
into fresh Sabouraud dextrose agar plates, which were
then incubated at 35°C for 48 h. Fungicidal effects were
considered significant when the MFC value was ≤ 4 ×
MIC value. Above this value, the antifungal effect was
considered fungistatic [24].
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Treatment of biofilms with antifungal agents
To evaluate the effect of antifungals on biofilm formation,
we used a protocol modified from previously described
assays for C. albicans biofilm formation and antifungal
treatment [25,26]. Aliquots of 100 μL of C. albicans ATCC
10231 yeast suspensions (1 × 107 CFU/mL, in RPMI 1640
medium buffered with 0.16 MOPS and supplemented with
2% glucose) were transferred into each well of polystyrene,
flat-bottomed 96-well plates, and incubated at 35°C under
constant agitation for 1.5 h. Then, supernatants were gen-
tly aspirated to remove any remaining non-adhering cells,
and 100 μL of fresh medium with or without antifungal
agents were added to the wells.
The choice of antifungal agent concentrations to be
tested against biofilms was based on MIC values ob-
tained for the treatment of planktonic cells. The follow-
ing concentrations of antifungal agents were tested: 0.5,
2, 8 and 32 μg/mL of AMB; 2, 8, 32 and 64 μg/mL of
FLC; and 31.25, 125, 500 and 1,000 μg/mL of fraction
F2 or subfraction F2.4. After the addition of antifungal
agents, plates were incubated for 24 or 48 h at 35°C
under constant agitation.
To evaluate the susceptibility of mature biofilms to anti-
fungal agents, biofilm formation was allowed to proceed
for 24 h at 35°C. After mature biofilms were formed, the
supernatant was removed, 100 μL of fresh medium with
or without antifungal agents (in the same concentrations
described above) were added to the wells, and the plates
were incubated for a further 24- or 48-h period, at 35°C
and under constant agitation.
After biofilm formation in the presence of the antifun-
gals or mature biofilm treatment, the supernatant con-
taining the dispersive cells was collected in eppendorf
tubes for future analysis and the biofilm was quantified
using two different approaches.
Metabolic activities of sessile and dispersion cells from
C. albicans biofilms after antifungal treatments (during
biofilm formation or on mature biofilm) were measured
using a tetrazolium reduction (XTT) assay [25]; and the
biofilm total biomass was quantified by crystal violet-
based assays [27].
Scanning electron microscopy (SEM)
C. albicans ATCC 10231 biofilms were formed over 5-mm
sections of central venous catheters (CVCs), as previously
described [28], in the presence or absence of antifungal
agents at concentrations corresponding to 64 × MIC (32
μg/mL AMB, 1,000 μg/mL fraction F2 or subfraction F2.4).
Antifungal treatments were also performed on mature
biofilms. Catheters containing biofilms were fixed in 2.5%
glutaraldehyde and 4% formaldehyde, in 0.1 M cacodylate
buffer, for 1 h at room temperature, and post-fixed in
1% osmium tetroxide and 1.25% potassium ferrocyanide
(in 0.1 M cacodylate buffer) for 30 min. The samples
were dehydrated in ethanol increasing concentrations,
critical-point-dried in CO2, coated with gold and ob-
served in a FEI-Quanta 250 scanning electron micro-
scope (FEI, Japan).
Statistical analyses
Statistical analyses were performed on the PRISM 5.0 soft-
ware (Graphpad, USA), using the Dunnett’s test (one-way
analysis of variance). Statistical significance was accepted
when p < 0.05.
Results and discussion
The main objective of the present work was to evaluate
the effect of fractions F2 and subfraction F2.4 (proantho-
cyanidins polimeric tannins) from S. adstringens against
C. albicans biofilm formation and mature biofilms (previ-
ously formed for 24h before drug treatment). S. adstrin-
gens was selected for this work because it is commonly
used in the treatment of vaginal infections in Brazil, where
C. albicans is the main fungal pathogenic species [2].
Given that biofilm cells are notoriously more resistant
to antifungal therapy than planktonic (suspension) cells
[19,20,29], we evaluated the inhibitory activity of S.
adstringens fractions on C. albicans ATCC 10231 biofilms
using concentrations of these fractions higher than the
MIC values determined on planktonic cells. Kuhn and co-
workers [30] reported that anti-biofilm activity is achieved
at considerably higher drug concentrations (8-32 and 32-
1,024 fold, for AMB and FLC, respectively) than those
used for planktonic cell growth inhibition. Considering
that fraction F2 and subfraction F2.4 behaved similarly
to FLC and AMB when tested against planktonic cells,
we defined that our analysis should cover concentra-
tions up to 64 fold the MIC value for planktonic cells,
which represented the higher limit of the therapeutic
range of these fractions.
C. albicans ATCC 10231 planktonic cells were suscep-
tible to treatment with fraction F2 and subfraction F2.4
(MIC values of 15.6 μg/mL for both). The MIC values
obtained for C. albicans ATCC 10231 were slightly higher
than those previously observed by our group for other iso-
lates of Candida spp. (MIC values between 0.97 and 7.80
μg/mL) [7]. For comparison, MIC values for FLC (1 μg/
mL) and AMB (0.5 μg/mL) were also determined in paral-
lel. MFC values revealed that only AMB had a fungicidal
effect, whereas FLC, F2 and F2.4 had fungistatic effect
against planktonic cells (MFC values of 1 μg/mL for
AMB, 64 μg/mL for FLC, and 250 μg/mL for both F2
and F2.4).
S. adstringens fractions presented an inhibitory activity
against C. albicans ATCC 10231 biofilms formation
comparable to the standard antifungals (AMB and FLC)
(Figure 1). F2 and F2.4 were also active against mature
biofilm sessile cells (Figure 2), and against dispersed
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cells from biofilm (Figure 3). On the other hand, the
standard antifungal FLC, which prevents biofilm forma-
tion, does not affect the metabolic activity of sessile cells
from mature biofilm, neither the spread of infection by
biofilm dispersion cells (Figures 1, 2 and 3).
All antifungal tested here caused a dose-dependent de-
crease in the metabolic activity of biofilm sessile cells
with a highest antifungal activity observed after 24 h of
treatment, during biofilm formation (Figure 1A-D). AMB
was the most active antifungal and concentrations as low
Figure 1 Effect of fraction F2 and of subfraction F2.4 from Stryphnodendron adstringens on the biofilm formation of Candida albicans
ATCC 10231. The metabolic activity of biofilm sessile cells was quantified using an XTT assay (A–D) and total biofilm biomass was quantified
using a cristal violet-based assay (E–H), after growth in the presence of amphotericin B (A and E), fluconazole (B and F), F2 (C and G) or F2.4
(D and H), for 24 or 48h, at 35°C, and under agitation. The error bar represents the standard error of the mean. *p < 0.05; **p < 0.01; ***p < 0.0001
(compared to untreated biofilms, using the Dunnett’s test).
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as 2 μg/mL (4 × MIC) of this drug were able to inhibit up
to 78% and 57% of biofilm sessile cells metabolism at 24 h
and 48 h, respectively. Total inhibition of biofilm sessile
cells metabolism (98% at 24 h of incubation) was
observed at concentration ≥ 8 μg/mL (≥16 × MIC) of
AMB (Figure 1A). FLC inhibited 52% of biofilm sessile
cells metabolism after 24 h or 48 h, when 2 μg/mL (2 ×
MIC) were used, and only 41% of biofilm sessile cells
Figure 2 Effect of fraction F2 and of subfraction F2.4 from Stryphnodendron adstringens on mature biofilms of Candida albicans ATCC
10231. The metabolic activity of biofilm sessile cells was quantified using an XTT assay (A–D), and the total biofilm biomass was quantified using
a cristal violet-based assay (E–H). Biofilms formed for 24h at 35°C were treated for 24 or 48h, at 35°C (and under agitation) with amphotericin B
(A and E), fluconazole (B and F), F2 (C and G) or F2.4 (D and H). The error bar represents the standard error of the mean. *p < 0.05; **p < 0.01;
***p < 0.0001 (compared to untreated biofilms, using the Dunnett’s test).
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metabolism after 48 h of incubation, using the max-
imum concentration of 64 μg/mL (64 × MIC) during
biofilm formation (Figure 1B).
Among the S. adstringens fractions tested here, sub-
fraction F2.4 significantly inhibited biofilm sessile cells
metabolism at concentrations ≥ 31.25 μg/mL (2 × MIC)
(p < 0.05) (Figure 1D). However, the greatest effect was
observed at concentration ≥ 500 μg/mL (≥32 × MIC),
when 72% inhibition of biofilm sessile cells metabolism
was observed after 24 h of incubation, and 60% inhib-
ition after 48 h (Figure 1D). The effect of fraction F2 on
the metabolism of biofilm sessile cells was less pro-
nounced after 24h of biofilm formation (up to 47% in-
hibition at 1,000 μg/mL), and no significant inhibitory
effect was observed after 48 h of incubation (Figure 1C).
Further, metabolic activity quantification revealed that
subfraction F2.4 was more effective at inhibiting biofilm
formation than fraction F2 (Figures 1C and D).
The total biofilm biomass after treatment with antifun-
gal during biofilm formation, including both viable and
non-viable cells was quantified using a CV staining assay
(Figures 1E-H). Despite the reduction in biofilm meta-
bolic activity after treatment with F2 and F2.4, there was
no significant change in the total biofilm biomass even
after 48 h of incubation with the highest concentrations
of these fractions. However, AMB treatment resulted in
a dose-dependent reduction of the total biofilm biomass,
with complete inhibition of biofilm formation at concen-
trations ≥ 8 μg/mL (≥16 × MIC) (p < 0.001), comparing
to the untreated group (Figure 1E). Also, a reduction in
Figure 3 Effect of fraction F2 and of subfraction F2.4 from Stryphnodendron adstringens on dispersion cells from biofilms of Candida
albicans ATCC 10231. The metabolic activity of dispersion cells was estimated using an XTT assay, using dispersion cells collected from biofilms
under formation (A – C) or mature (formed for 24h at 35°C, prior to the start of treatment) (D – F). Biofilms were treated for 24 or 48h at 35°C
with fluconazole (A and D), F2 (B and E) or F2.4 (C and F). Dispersion cells from biofilms treated with amphotericin B were not analyzed, since
these were found in insufficient numbers to allow accurate quantification. The error bar represents the standard error of the mean. **p < 0.01;
***p < 0.0001 (compared to untreated biofilms, using the Dunnett’s test).
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the biofilm biomass of 32-50% was observed with FLC
treatment at concentrations ≥ 2 μg/mL (≥2 × MIC) after
48 h of incubation (p < 0.001; Figure 1F).
Mature biofilms of C. albicans ATCC 10231 were less
susceptible to AMB than biofilms under development
(Figure 2A). Treatment with 2 μg/mL (4 × MIC) AMB
resulted in an inhibition of 44% and 13% of biofilm sessile
cells metabolic activity, after 24 h and 48 h of incubation,
respectively (Figure 2A). When 32 μg/mL (64 × MIC) of
AMB was used, reductions of 82% and 65% in sessile cells
metabolism were achieved, after 24 h and 48 h of treat-
ment, respectively (Figure 2A). Although FLC treatment
resulted in higher inhibition of biofilm formation com-
pared to fractions from S. adstringens (Figure 1B-D), FLC
had no significant effect on mature biofilms at any of the
concentrations tested (Figure 2B), while treatment of
mature biofilms for 24 h with 1,000 μg/mL (64 × MIC) of
fraction F2 or of subfraction F2.4 reduced by 47% and
51% the metabolic activity of mature biofilm sessile cells,
respectively (Figure 2C and D).
Treatment of mature biofilms with AMB resulted in a
dose-dependent reduction in biofilm biomass (Figure 2E),
matching the corresponding reduction in biofilm meta-
bolic activity after treatment (Figure 2A). AMB induced
a prominent reduction of mature biofilm biomass (37-
80%) at concentrations ≥ 2 μg/mL (≥4 × MIC; p < 0.001),
after 48 h of incubation, comparing to the untreated
group (Figure 2E). The total biomass of mature biofilms
was not reduced after treatment with FLC, fraction F2 or
subfraction F2.4 at concentrations up to 64 × MIC after
both 24 and 48 h incubation periods (Figure 2F-H), des-
pite the decrease in metabolic activity observed on biofilm
cells after treatment with F2 and F2.4 (Figure 2C and D).
In addition, the total biomass of mature C. albicans
biofilms increased in comparison with the untreated
group after 24 h of incubation with F2 or F2.4 (Figure 2G
and H). We hypothesized that this could be happening
for two reasons: (i) metabolically inactive cells remain
attached to biofilms upon drug treatment, contributing
to maintain biofilm biomass; and/or (ii) the extracellular
matrix (ECM) of biofilms increases during treatment, as
a protective mechanism against proantocyanidin poly-
meric tannins from S. adstringens.
In C. albicans biofilms, the ECM can prevent antifun-
gal agent penetration into the innermost biofilm layers
[20], acting as a physical barrier to protect cells embed-
ded in the biofilm community from the access of anti-
microbial agents, thus increasing biofilm drug resistance.
The efficiency of the ECM as an ‘obstacle’ to drug pene-
tration seems to depend on the amount and nature of
the matrix, as well as on the physicochemical properties
of the antifungal drug [20]. Further, the ECM quantifica-
tion assays performed on treated biofilms should clarify
the importance (if any) of increased ECM production in
biofilm biomass maintenance during treatment with FLC,
F2 or F2.4.
Fractions F2 and subfraction F2.4 from S. adstringens
were more effective at inhibiting biofilm formation, but
these fractions were also active against mature biofilms.
Still, both fraction F2 and subfraction F2.4 were more
effective against mature biofilms than FLC, which did
not affect pre-formed biofilms (Figure 2A-D). Biofilms
are considerably more resistant to antifungal drugs than
planktonic cells, and this statement is particularly true
for azoles (such as FLC) [19,29]. Indeed, despite the poor
effectiveness of FLC against biofilms, this drug is the
first option for the treatment of superficial and mucosal
Candida infections [29]. Although fractions F2 and F2.4
were overall less effective than AMB against C. albicans,
previous works showed that extracts from S. adstringens
are less toxic to red blood cells and to epithelial cells
than polyene agents (such as AMB) [13]. Still, doses used
in this work were safely within the therapeutic window re-
ported for fraction F2 in rodent models [17,18]. Absence of
F2 genotoxicity to mice at concentrations as high as 2,250
mg/kg were also reported [17]. Lethal dose of 3,015 mg/kg
[18] and chronic treatment for 90 days with 100-200 mg/
kg did not affect blood biochemical parameters or tissue
morphology as demonstrated by Costa et al. [18].
During biofilm development, cells that become detached
from biofilms are known as ‘dispersion cells’ [31]. These
cells are particularly important for disease progression, be-
cause they may colonize other sites in the host, expanding
the infection or, in the worst case scenario, starting a
disseminated infection [31]. This cells display distinct
virulence properties when compared to their planktonic
counterparts, including enhanced adherence, filamenta-
tion, biofilm formation, and increased pathogenicity in a
murine model of hematogenously disseminated candid-
iasis [31]. The dispersion cells from biofilms were also
analysed in this work (except for those from AMB treated
samples, where biofilm growth was too insipid to yield a
sufficient number of dispersion cells for analysis). Disper-
sion cells from biofilm formation or from mature biofilms
displayed a dose-dependent reduction in metabolic activ-
ity after treatment with S. adstringens fractions, and this
effect was more pronounced for the subfraction F2.4 than
for fraction F2 (Figure 3B-F). Dispersion cells from bio-
films formed in the presence of S. adstringens fractions at
concentrations ≥ 31.25 μg/mL (≥2 × MIC) had signifi-
cantly reduced metabolic activity in comparison to those
released from untreated biofilms after 24 h or 48 h of
treatment (fraction F2, 49-83% of inhibition; subfraction
F2.4, 61-89% of inhibition) (Figure 3B and C). Both frac-
tions yielded metabolic activity inhibition in dispersion
cells above 50%, as early as 24 h after the start of treat-
ment on mature biofilm at concentrations ≥ 500 μg/mL
(≥32 × MIC) (p < 0.001) (Figure 3E and F). Moreover, F2
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and F2.4 were significantly more effective at reducing the
metabolic activity of dispersion cells from biofilms than
treatment with FLC, where dispersion cell metabolic
activity was similar to that observed in the untreated
group (Figure 3A and D). These exciting results suggest
that treatment with proantocyanidins polymer-rich frac-
tions from S. adstringens stem bark might be able to
prevent the dissemination of C. albicans infections, due
to its effect on metabolic activity of dispersion cells.
Morphological effects on C. albicans biofilms treated
with AMB, F2 and F2.4 were evaluated by scanning elec-
tron microscopy (SEM) images (Figures 4 and 5). Un-
treated C. albicans biofilms showed a dense network of
filamentous form fungi formed for 24 h (biofilm formation
assay) (Figure 4A-C) and 48 h (mature biofilm assay)
(Figure 5A-C). Treatment with AMB inhibited the fungal
filamentation process with most biofilm cells retaining the
yeast form (Figure 4D-F; Figure 5D-F). Treatments with
fraction F2 or subfraction F2.4 (Figure 4G-L; Figure 5G-L)
induced alterations mainly in blastoconidia, with the
formation of ‘dumbbell-shaped’ cells (white arrows in
Figures 4I, L and 5I, L), suggestive of an effect on the
budding process, as previously described for C. albicans
planktonic cells treated with subfraction F2.4 [7]. Treat-
ment with F2.4 also induced the arising of blastoconidia
clusters in biofilms (Figures 4K, L and 5K, L), similarly
Figure 4 Scanning electron microscopy of Candida albicans ATCC 10231 biofilms formed in the presence of fraction F2 or subfraction
F2.4 from Stryphnodendron adstringens. Biofilms were treated with antifungal agents concentrations 64 fold higher than the minimum
inhibitory concentration (MIC) values determined for the treatment of planktonic cells for 24-h incubations at 35°C. Compared to untreated
controls (A-C), biofilms formed in the presence of 32 μg/mL amphotericin B (D-F) displayed a reduction in fungal biomass, with filamentation
inhibition and the presence of irregular buds (arrows in F). Treatment with 1,000 μg/mL of fraction F2 (G-I) or subfraction F2.4 (J-L) led to the
formation of biofilms with blastoconidia cells of altered shape, including ‘dumbell’ cells (I and L, arrows) and those with elongated bud necks
(L, arrowhead). Scale bars: 1 mm (A, D, G and J), 20 μm (B, E, H and K) and 10 μm (C, F, I and L).
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to previous results of our group for C. albicans plank-
tonic cells treated with subfraction F2.4 [7].
Proanthocyanidins are oligomeric flavonoids composed
by derivatives of catechin and epicatechin and their
gallic acid esters. More complex structures composed
of the same polymeric building blocks form the group
of condensed tannins. The present work is the first re-
port of the activity of proanthocyanidins polymeric tan-
nins against fungal biofilms. However, other reports
have demonstrated the antifungal the activity of flavon-
oid molecules against planktonic cells of yeast [32,33]
and filamentous fungi [34]. Recently, Shahzad et al. [35]
described the inhibitory activity of some monomeric
polyphenols, including flavonoids, on planktonic cells of
C. albicans and on C. albicans biofilms (at concentra-
tions 78.12 - >1,000 μg/mL and 39.06 - >5,000 μg/mL,
respectively).
Subfraction F2.4 was obtained from the aqueous frac-
tion F2 by chromatography using a Sephadex LH-20
column [7], and was identified as a polymeric tannin of
molecular weight of 2,114 Da, composed of six mono-
mers of proanthocyanidins (prodelphinidin and prorobi-
netinidin) and gallic acid residues [5-7]. The degree of
polymerization of polyphenols appears to be related to
antifungal activity, possibly because the reactivity of tan-
nins with macromolecules (including both proteins and
Figure 5 Scanning electron microscopy of mature biofilms from Candida albicans ATCC 10231 treated with fraction F2 or subfraction
F2.4 from Stryphnodendron adstringens. Mature biofilms formed during 24-h incubations at 35°C were treated for an additional 24h in the
same conditions, with antifungal agent concentrations 64 fold higher than the minimum inhibitory concentration (MIC) values determined for
the treatment of planktonic cells. Compared to untreated controls (A-C), mature biofilms treated with 32 μg/mL amphotericin B (D-F) induced a
reduction in the fungal biomass. Treatment with 1,000 μg/mL of fraction F2 (G-I) or subfraction F2.4 (J-L) induced the formation of elongated
blastoconidia cells (arrows in I and L), and treatment with subfraction F2.4 also induced the formation of blastoconidia clusters (arrow in L). Scale
bars: 1 mm (A, D, G and J), 20 μm (B, E, H and K), 10 μm (C, F, I and L).
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carbohydrates) increases progressively with the degree of
polymerization [36,37].
The antifungal properties of S. adstringens against
planktonic cells of Candida spp. and C. neoformans have
been attributed to this polymeric tannin [7,16]. Our data
demonstrate that proantocyanidin polymeric tannin-rich
fractions from S. adstringens stem bark (fraction F2 and
subfraction F2.4) are also active against biofilms of C. albi-
cans, likely due to the presence of this proantocyanidins
polymeric tannin in these fractions. At safe doses, both F2
and F2.4 inhibited biofilm formation and reduced the
metabolic activity of mature biofilm cells. Interestingly,
these fractions also reduced the metabolic activity of dis-
persion cells, indicating that they could inhibit infection
dissemination mediated, at least in part, by this cell popu-
lation. Thus, these polymeric tannins can affect a particu-
larly drug-resistant stage of biofilm development.
Conclusion
This is the first report of the anti-biofilm activity of
proanthocyanidins polymeric tannins from S. adstringens
stem bark (fraction F2 and subfraction F2.4) and being
an important finding, since the development of new and
cheaper compounds for the treatment of biofilm-related
fungal infections is sorely needed. Therefore, fraction F2
and subfraction F2.4 from S. adstringens shows great
potential in the search for new therapy against Candida
infections involving biofilm formation.
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